Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug-delivery platforms, recently announced further advances in
its proprietary, oral, drug-delivery platform: DehydraTECH(TM). An article
discussing the company reads, “Lexaria’s early pilot-stage human trials with
tetrahydrocannabinol (THC) delivery show its newest formulation of
DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less
than 10 minutes, which is about twice as fast as traditional DehydraTECH and
four to six times faster than generic industry formulations, according to a
company news release (http://ibn.fm/mwAS9).
. . . Lexaria has been developing DehydraTECH solutions as alternatives to
smoked or vaped drug delivery over the course of the past three years,
establishing a means whereby edible consumption of certain substances can
provide results at rates comparable to inhaled substances and faster than
ingested substances in general.”
To view the full article, visit http://ibn.fm/ys4jC
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
